Endocrine Testing Market Size, Growth, Shares and Key Trends 2025

Market size

Base and near-term values

●2024 market size (reported): USD 2.99 billion.

●2025 market size (reported): USD 3.24 billion.

Long-term projection

●Projected 2034 market size (reported): USD 6.75 billion.

Growth metrics

●Reported CAGR for 2025–2034: 8.54%.

●Absolute projected increase from 2025 to 2034: USD 6.75B − USD 3.24B = USD 3.51 billion additional market value over that period.

Regional weighting (scale & concentration)

●North America: 38% of global revenue in 2024 (dominant single region).

●Asia-Pacific: fastest growing region (no single % provided, but called out as highest CAGR region).

Major revenue drivers inside headline numbers

●Instruments & reagents accounted for 65% of market revenue in 2024 (largest revenue stream).

●Clinical & hospital laboratories accounted for 58% of end-user revenue in 2024 (largest end-user channel).

●Automated immunoassays comprised 52% of assay/platform revenues in 2024 (largest technology share).

●Diagnostic & monitoring of thyroid & diabetes comprised 60% of indications revenue in 2024 (largest indication group).

●Thyroid function tests alone were 38% of test-type share in 2024 (single most dominant test family).

Concentration / structure

●The market shows high instrument + reagent dependency (65% revenue share) — implying recurring consumable sales dominate monetization.

●Large labs/hospitals are primary buyers (38% regional + direct OEM sales dominance), indicating centralized procurement and long OEM relationships.

Market trends

Rising disease prevalence and screening expansion

●Diabetes and thyroid disease continue to drive baseline testing volumes (cited IDF 2025: 11.1% of adults 20–79 have diabetes; many undiagnosed), which supports routine testing demand and chronic monitoring volumes.

Shift to automation and high-throughput platforms

●Automated immunoassays held 52% share in 2024 — labs are consolidating around automated analyzers to handle large volumes, reduce TAT, and standardize results.

LC-MS/MS adoption for specialty assays

●Laboratory mass spectrometry (LC-MS/MS) marked as the fastest-growing assay platform, driven by demand for high specificity in steroid and low-level hormone panels.

Commercial models moving toward services

●Growth in contract testing/reference lab services and lab-as-a-service/send-outs—these service models are the fastest-growing revenue streams and distribution channels, allowing smaller clinics to access advanced assays without capital spend.

POC and at-home testing emergence

●Point-of-care glucose and at-home hormone tests (examples in the content) are expanding the testing universe beyond the lab and creating new consumer revenue channels.

Inorganic growth and partnerships

●M&A and partnerships (e.g., the Norman Parathyroid Center partnership) are being used to expand test access and referral flows quickly.

Funding into consumer/remote hormone testing

●Startups raising seed and pre-seed rounds (Hormona, Level Zero Health, Eli Health) show investor interest in remote monitoring, DNA/sensor technologies, and consumer-facing hormone tools.

Regulatory activity enabling new tests

●FDA 510(k) clearances (example: chemiluminescence free testosterone assay) enable faster clinical uptake of newer, faster assays.

Reimbursement and policy remain pivotal

●Favorable reimbursement in developed markets (cited for North America) continues to sustain higher per-test revenue and tech adoption.

AI impact / role

AI-assisted result interpretation and decision support

●Subpoint: Algorithms can analyze multi-analyte patterns (e.g., combinations of TSH, free T4, antibodies) to flag likely disease states or borderline results.

●Explanation: This reduces clinician diagnostic uncertainty, creates standardized interpretative comments, and minimizes follow-up testing due to ambiguous reports.

Automated QC and anomaly detection

●Subpoint: AI monitors instrument telemetry and assay performance to detect drift, lot issues, or pipetting anomalies in real time.

●Explanation: Proactive QC reduces false results, lowers repeat testing rates (cost saving), and supports laboratory accreditation efforts.

High-throughput data processing for LC-MS/MS

●Subpoint: Machine learning accelerates deconvolution of complex spectral data and improves peak integration for low-abundance hormones.

●Explanation: Improves sensitivity/specificity of steroid panels and reduces manual review time for mass spec results.

Predictive analytics for population screening

●Subpoint: AI models can combine historical lab data, demographic risk, and clinical notes to prioritize patients for targeted endocrine screening (e.g., undiagnosed diabetes or hypothyroidism).

●Explanation: In public health programs, this increases yield per screening dollar and helps allocate resources more efficiently.

Workflow orchestration & lab automation

●Subpoint: AI optimizes sample routing between automated analyzers, LC-MS/MS instruments, and send-out labs to minimize TAT and reagent wastage.

●Explanation: Especially valuable for labs operating hybrid automated + specialty workflows.

Personalized reference ranges & longitudinal trend detection

●Subpoint: AI builds individualized baselines from longitudinal hormone data (e.g., cyclical reproductive hormones) and flags meaningful deviations.

●Explanation: Reduces false alarms from single point testing and improves infertility or endocrine disorder management.

Integration with wearables and remote monitoring

●Subpoint: AI fuses periodic lab tests with continuous physiologic streams (sleep, HR variability, activity) to infer endocrine stressors (e.g., cortisol dynamics).

●Explanation: Enables novel remote monitoring services and chronic disease management products.

Clinical trial support & biomarker discovery

●Subpoint: Unsupervised learning to discover new endocrine biomarkers or composite indices predictive of disease progression or therapy response.

●Explanation: Creates upstream R&D value, boosting assay development pipelines.

Revenue & business model transformation

●Subpoint: AI enables value-based testing (predictive algorithms that reduce downstream costs) and subscription/monitoring services tied to automated interpretative reporting.

●Explanation: Shifts some spend from one-time tests to ongoing analytics services—aligns with instruments & reagents dominance (consumables) plus software/licensing revenue.

Regulatory, validation, and explainability challenges

●Subpoint: AI models used clinically need documented performance, transparency, and post-market monitoring—regulatory pathways are evolving.

●Explanation: Labs and vendors must invest in clinical validation, explainability tools, and data governance to deploy AI at scale.

Data privacy & interoperability concerns

●Subpoint: Combining lab results with EHR and wearables requires secure data exchange, consent models, and standardized APIs.

●Explanation: Failure to address privacy impedes adoption and may limit payer reimbursement for AI-enabled services.

Operational risk reduction

●Subpoint: AI can predict supply chain shortages (e.g., critical reagents) and recommend substitutions or schedule changes.

●Explanation: Helps labs avoid downtime and ensures continuity for high-volume endocrine tests.

Regional insights

North America (dominant; 38% share in 2024)

Market structure & drivers

●Large hospital systems and clinical labs with centralized procurement favor OEM direct sales and long-term service contracts.

●Reimbursement frameworks and public health programs (e.g., diabetes screening programs) sustain high per-capita test volumes.

Technology adoption

●High penetration of automated immunoassay platforms (52% share) and rapid adoption of LC-MS/MS for specialty assays.

Commercial implications

●Vendors prioritize instrument availability, on-site service, and reagent contracts; reference labs (LabCorp, Quest, ARUP) absorb complex send-outs.

Regulatory/innovation environment

●FDA clearances (example: free testosterone chemiluminescence assay) speed clinical adoption.

Asia-Pacific (fastest growth region)

Demand drivers

●Rising diabetes and thyroid disease prevalence, expanding healthcare infrastructure, and greater disposable income.

Market dynamics

●Significant upside for OEMs through distributorships and localized service networks; labs move from manual to automated platforms.

Country subpoints

●India and China: large addressable populations and increasing screening programs; early adopter hospitals in metros drive premium test uptake.

Challenges

●Variable reimbursement, fragmented lab networks, need for training & workforce development.

Europe

Health system diversity

●Mix of public and private provision; centralized procurements in some countries (e.g., NHS in UK).

Technology & R&D

●Strong clinical research networks and adoption of high-specificity assays; emphasis on quality and interoperability.

Latin America and MEA

Access & growth

●Lower baseline per-capita testing but high growth potential where screening programs are scaled.

Barriers

●Infrastructure, reimbursement limits, and workforce shortages slow adoption of advanced assay platforms.

Country specifics highlighted in content

United States

●High disease burden (CDC figures cited in content) and supportive programs such as NDPP; major purchasing power and high lab automation.

Canada

●Rapid expansion of POC and digital health tools; provincial health programs support preventive screening.

Market dynamics

Drivers

High prevalence of endocrine disorders

●Diabetes prevalence (IDF 2025: 11.1% of adults 20–79) and large numbers with thyroid disease support sustained testing demand.

Government screening & preventive programs

●Screening programs push routine testing volumes (noted as a key driver).

Technology advancements

●Automated immunoassays and LC-MS/MS increase throughput and diagnostic accuracy.

Recurring consumable revenue

●Instruments & reagents account for 65% of revenue, creating stable vendor cash flow.

Restraints

Shortage of skilled laboratory operators

●Limits capacity to adopt complex assays and to scale LC-MS/MS despite technical need.

Regulatory hurdles

●Lengthy approvals delay commercialization of new assays and AI tools.

Reimbursement limitations in some countries

●Limits patient access and dampens demand growth in markets without favorable coverage.

Opportunities

Reference/Contract testing growth

●Outsourcing provides access to advanced assays without heavy capital outlay; fastest growing end-user segment.

Infertility & reproductive endocrinology

●Reproductive hormone tests are fastest-growing test type due to infertility trends and ART uptake.

AI-enabled services and remote monitoring

●Creates new service layers (analytics/subscriptions) and improved disease monitoring.

Point-of-care and consumer testing expansion

●At-home cortisol/progesterone and POC HbA1c/glucose broaden market reach.

Top companies

Roche Diagnostics

●Product: Automated immunoassay analyzers, reagent kits, integrated lab automation.

●Overview: Market leader in high-throughput immunoassays; large installed base in hospitals and reference labs.

●Strengths: Strong reagent lifecycle (recurring revenue), global service network, broad assay menu (thyroid, diabetes, reproductive panels).

Abbott Diagnostics

●Product: Lab and point-of-care platforms (immunoassays, POC glucose/HbA1c), reagents.

●Overview: Dual strength in lab systems and POC solutions; strong presence in decentralized testing.

●Strengths: POC leadership, established reagent supply chain, diversified diagnostics portfolio.

Siemens Healthineers

●Product: Clinical chemistry and immunoassay analyzers, connectivity solutions.

●Overview: Major supplier to hospital labs; strong systems integration and service offerings.

●Strengths: Enterprise contracts, integration with hospital IT and LIS.

Beckman Coulter

●Product: Immunoassay analyzers and diagnostics reagents.

●Overview: Focus on clinical lab instrumentation and assay chemistry.

●Strengths: Robust analyzer platforms, built for high throughput labs.

Ortho Clinical Diagnostics

●Product: Immunoassay systems and reagents.

●Overview: Known for chemiluminescence and immunoassay test menus.

●Strengths: High throughput workflows and trusted assays for endocrine analytes.

Thermo Fisher Scientific

●Product: LC-MS/MS instrumentation, sample prep solutions, lab supplies.

●Overview: Strong in mass spectrometry and specialty testing instrumentation.

●Strengths: Technical leadership in LC-MS/MS (key for steroid and low-abundance hormone assays).

Agilent Technologies

●Product: Mass spectrometers, chromatography systems, lab consumables.

●Overview: Supplier to labs requiring high-sensitivity mass spec and separation technologies.

●Strengths: Analytical performance and support for research/clinical labs.

Waters Corporation

●Product: LC and mass spec systems optimized for clinical and research mass spec assays.

●Overview: Specialist in separations and MS workflows for endocrinology assays.

●Strengths: High-quality LC-MS workflows for steroid panels and specialty assays.

Bio-Rad Laboratories

●Product: Controls, calibration materials, some immunoassay reagents and QC products.

●Overview: Supplies many labs with QA/QC and reagent products that support endocrine testing reliability.

●Strengths: Strong reputation for controls and quality materials.

Other important players

●Tosoh Bioscience, Snibe/Mindray, Fujirebio, QuidelOrtho (assay suites), LabCorp, Quest Diagnostics, ARUP — collectively create the testing & reference lab backbone.